AbbVie Q1 adj EPS $2.46 (+6.5%), revenue $13.34B (+8.4%); raises FY EPS guidance to $12.09-$12.29

AbbVie Inc.

2025-Q1 EPS reported $0.72 revenue$13,343,000,000

Q1 GAAP EPS $0.72 (down 6.5%), adjusted EPS $2.46 (up 6.5%); revenue $13.34B (+8.4% reported).
Immunology growth: Skyrizi $3.43B (+70.5%), Rinvoq $1.72B (+57.2%); Humira $1.12B (-50.6%).
Aesthetics down 11.7% to $1.10B; Botox Cosmetic -12.3%, Juvederm -22.2%.
FY2025 adjusted diluted EPS guidance raised to $12.09-$12.29 from $11.99-$12.19.
CEO Robert A. Michael elected chairman effective July 1, 2025, succeeding Richard A. Gonzalez.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.